Skip to main content
H

HANS BIOMED CORPORATION — Investor Relations & Filings

Ticker · 042520 ISIN · KR7042520007 KO Manufacturing
Open in API
Filings indexed 230 across all filing types
Latest filing 2026-05-04 Regulatory Filings
Country KR South Korea
Listing KO 042520

About HANS BIOMED CORPORATION

http://www.hansbiomed.com/en/

HANS BIOMED CORPORATION is a biotechnology company that develops, manufactures, and sells high-tech medical materials, devices, and biologics. The company's core focus is on regenerative medicine and tissue engineering. Its product portfolio includes silicone breast implants, allograft tissue products for skin and bone grafts, and absorbable lifting sutures for aesthetic procedures. The company also offers professional cosmeceutical products. HANS BIOMED supports its operations through a dedicated tissue engineering research laboratory and a human tissue bank, aiming to provide innovative solutions for the global medical and aesthetic markets.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(약식)
Regulatory Filings
2026-05-04 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 1% confidence The document is a Korean “주식등의 대량보유상황보고서(약식)” – a report of large shareholdings, detailing changes in share counts and percentages by the reporting entity and its affiliates. This corresponds to a Major Shareholding Notification, reporting crossing threshold and changes in substantial holdings. Therefore, it matches the MRQ category.
2026-04-09 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea (often referred to as a 5% report). It details the shareholding changes of KB Asset Management in Hans Biomed Co., Ltd. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks changes in significant ownership levels.
2026-03-03 Korean
분기보고서 (2025.12)
Interim / Quarterly Report Classification · 1% confidence The document is a '분기보고서' (Quarterly Report) for HansBiomed Corp, covering the period from October 1, 2025, to December 31, 2025. It contains detailed financial data, business operations, management information, and capital structure, which aligns with the definition of an Interim/Quarterly Report (IR). Q4 2025
2026-02-13 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 1% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed in South Korea. This type of regulatory filing is required when an entity or individual crosses a significant ownership threshold in a publicly traded company. In the provided taxonomy, this corresponds to a 'Major Shareholding Notification'.
2026-01-26 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 1% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a regulatory filing required under the Capital Markets Act in South Korea when an entity or individual acquires a significant stake (typically 5% or more) in a publicly traded company. This document specifically details the shareholding status of Neo-Young Inc. and its special related parties in HansBiomed Corp. Since this is a formal regulatory disclosure regarding major shareholding thresholds, it falls under the 'Major Shareholding Notification' category.
2026-01-26 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.